Clinical Trial Update: An Efficacy and Safety Study With Vandetanib to Treat Inoperable or Relapsed Malignant Mesothelioma [Phase 2]

View source ↗

Summary

This entry reports that the Phase 2 trial of Vandetanib for inoperable or relapsed malignant mesothelioma has been terminated, with results posted in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Mesothelioma

Drugs mentioned

• Vandetanib (vandetanib)

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Mesothelioma | Phase 2 | Status: TERMINATED | Results posted: 2012-10-15